Efficacy of clofazimine-modified cyclodextrin against Mycobacterium avium complex in human macrophages

International Journal of Pharmaceutics

Volumn 260, Issue 1, 2003, Pages 105-114

  Salem, Isam Ismail ^a,b   Steffan, Gerhard ^a   Düzgünes, Nejat ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Clofazimine; Cytotoxicity; Efficacy; Macrophages; Modified cyclodextrin; Mycobacterium; Solubility

Indexed keywords

ANTIINFECTIVE AGENT; CLOFAZIMINE MODIFIED CYCLODEXTRIN COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; EVALUATION; HUMAN; HUMAN CELL; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL;

EID: 0038344724     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00236-9     Document Type: Article

References (27)

1. Anderson R., Zeis B.M., Anderson I.F. Clofazimine-mediated enhancement of reactive oxidant production by human phagocytes as a possible therapeutic mechanism. Dermatologica. 176:1988;234-242.
2. Cohn D.L., Fisher E.J., Peng G.T., Hodges J.S., Chesnut J., Child C.C., Franchino B., Gibert C.L., El-Sadr W., Hafner R., Korvick J., Ropka M., Heifets L., Clotfelter J., Munroe D., Horsburgh C.R. Jr. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Clin. Infec. Dis. 29:1999;125-133.
3. Damle P., McClatchy J.K., Gangadharam P.R. Antimicrobial activity of some potential chemotherapeutic compounds. Tubercle. 59:1978;135-138.
4. Duchene, D., 1987. Cyclodextrin and Their Industrial Uses. Editions de Santé, Paris.
5. Feng P.C., Fenselau C.C., Jacobson R.R. Metabolism of clofazimine in leprosy patients. Drug Metab. Dispos. 9:1981;521-524.
6. Feng P.C., Fenselau C.C., Jacobson R.R. A new urinary metabolite of clofazimine in leprosy patients. Drug Metab. Dispos. 10:1982;286-288.
7. Gangadharam P.R., Candler E.R. Activity of some antileprosy compounds against Mycobacterium intracellulare in vitro. Am. Rev. Respir. Dis. 115:1977;705-708.
8. Geigy Pharmaceuticals, 1986. Lamprene (Clofazimine) Prescribing Information. Ardsley, NY.
9. Konopka K., Pretzer E., Felgner P.L., Düzgünes N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim. Biophys. Acta. 3:1996;186-196.
10. Levy L. Clofazimine-resistant M. leprae. Int. J. Lepr. Other Mycobact. Dis. 54:1986;137-140.
11. Lindholm-Levy P., Heifets L. Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex. Tubercle. 69:1988;179-186.
12. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1996;1017-1025.
13. Masur H. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 329:1993;898-904.
14. Mathur A., Venkatesan K., Bharadwaj V.P. Evaluation of effectiveness of clofazimine therapy: monitoring of absorption of clofazimine from gastrointestinal tract. Ind. J. Lepr. 57:1985;146-148.
15. Oliva B., Comanducci A., Chopra Y. Antibacterial spectra of drugs used for chemotherapy of mycobacterial infections. Tubercle Lung Dis. 79:1998;107-109.
16. O'Reilly J.R., Corrigan O.L., O'Driscoll C.M. Effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B-663) in the anesthetized rat. Int. J. Pharm. 109:1994;147-154.
17. Peters K.S., Leitzke J.E., Diederichs K., Borner H., Muller H.R.H., Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45:2000;77-83.
18. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrin. 2. In vivo drug delivery. J. Pharm. Sci. 85:1996;1142-1169.
19. Reddy V.M., Nadadhur G., Daneluzzi D., O'Sullivan J.F., Gangadharam P.R. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother. 40:1996;633-636.
20. Reddy V.M., O'Sullivan J.F., Gangadharam P.R. Antimycobacterial activities of riminophenazines. J. Antimicrob Chemother. 43:1999;615-623.
21. van Rensburg C.E., Joone G.K., O'Sullivan J.F. Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates. Oncol. Rep. 7:2000;193-195.
22. van Rensburg C.E., van Staden A.M., Anderson R. The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res. 53:1993;318-323.
23. Salem I.I., Düzgünes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int. J. Pharm. 250:2003;403-414.
24. Siddiqi S., Libonati J.P., Middlebrook G. Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Microbiol. 13:1981;908-913.
25. Siddiqi S.H., Heifets L.B., Cynamon M.H., Hooper N.M., Laszlo A., Libonati J.P., Lindholm-Levy P.J., Pearson N. Rapid broth macrodilution for determination of MICs for Mycobacterium avium isolates. J. Clin. Microb. 9:1993;2332-2338.
26. Steffan, G., Salem, I.I., Düzgünes, N., 2002. Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung. German Patent, DE19814814C2.
27. Uekama K., Hirayama F., Irie T. Application of cyclodextrins in pharmaceutical preparations. Drug Target. Deliv. 3:1994;411-456.